Turning Point Therapeutics TPTX

HealthcareMarket cap $4B1 connection

Turning Point Therapeutics (acquired by Bristol-Myers Squibb for $4.1B) developed repotrectinib - a next-generation ROS1 inhibitor for lung cancer. The acquisition validated precision oncology drug development as a highly valuable approach. Its story inspired a new generation of biotech focused on kinase inhibitors for cancer.

Explore Turning Point Therapeutics on the interactive map Relationship timeline Find a path to another company

Owned by 1

Companies with a stake in Turning Point Therapeutics

Bristol-Myers SquibbHealthcare · $140BBristol Myers Squibb acquired Turning Point Therapeutics (2022)since 2022

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Turning Point Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=TPTX" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Turning Point Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.